NCT04453631

Brief Summary

The main goal of the study is to test the efficacy of tDCS in combination with the Unified Protocol for transdiagnostic treatment of emotional disorders, to reduce anxiety symptoms in a mixed anxiety disorders sample, as assessed by the Hamilton Anxiety Rating Scale (HARS; Hamilton, 1959).

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jan 2023

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 26, 2020

Completed
5 days until next milestone

First Posted

Study publicly available on registry

July 1, 2020

Completed
2.5 years until next milestone

Study Start

First participant enrolled

January 3, 2023

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2024

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2024

Completed
Last Updated

May 20, 2022

Status Verified

May 1, 2022

Enrollment Period

12 months

First QC Date

June 26, 2020

Last Update Submit

May 19, 2022

Conditions

Keywords

anxiety disorderstDCSUnified ProtocolRCT

Outcome Measures

Primary Outcomes (1)

  • Hamilton Anxiety Rating Scale (HARS; Hamilton, 1959)

    The mean change in the Hamilton Anxiety Rating Scale (HARS; Hamilton, 1959) score, from baseline. HARS total score ranges from 0 to 56, where higher values indicate higher anxiety symptom's severity.

    At week 8th, 15th (middle and end of treatment) and 6 months follow-up

Secondary Outcomes (3)

  • Response to treatment

    At week 8th, 15th (middle and end of treatment) and 6 months follow-up.

  • Remission to treatment

    At week 8th, 15th (middle and end of treatment) and 6 months follow-up.

  • Hamilton Depression Rating Scale (HRSD; Hamilton, 1960)

    At week 8th, 15th (middle and end of treatment) and 6 months follow-up.

Study Arms (4)

active tDCS + CBT-UP

EXPERIMENTAL

Active tDCS combined with the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders.

Device: active tDCSBehavioral: CBT-UP

sham tDCS + CBT-UP

ACTIVE COMPARATOR

Sham tDCS (control for active tDCS) combined with the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders.

Device: sham tDCSBehavioral: CBT-UP

active tDCS + Psychoeducation

ACTIVE COMPARATOR

Active tDCS combined with psychoeducation (control condition for CBT-UP).

Device: active tDCSBehavioral: Psychoeducation

sham tDCS + Psychoeducation

PLACEBO COMPARATOR

Sham tDCS combined with psychoeducation (control conditions for active tDCS and CBT-UP).

Device: sham tDCSBehavioral: Psychoeducation

Interventions

26 transcranial direct current stimulation sessions, each lasting 20 minutes, with a current intensity of 2 mA, the cathode placed over the right dorsolateral prefrontal cortex and the anode placed over the left deltoid muscle.

Also known as: Transcranial Direct Current Stimulation
active tDCS + CBT-UPactive tDCS + Psychoeducation
sham tDCSDEVICE

tDCS is controlled in this intervention: sham mode.

sham tDCS + CBT-UPsham tDCS + Psychoeducation
CBT-UPBEHAVIORAL

15 psychotherapy sessions (1/week) following the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders developed by Barlow et al. 2018.

active tDCS + CBT-UPsham tDCS + CBT-UP
PsychoeducationBEHAVIORAL

To control for the cognitive-behavioral intervention we will use psychoeducation materials.

active tDCS + Psychoeducationsham tDCS + Psychoeducation

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Diagnosis of generalized anxiety disorder, specific phobia, panic disorder, agoraphobia, or social anxiety disorder.
  • Willing to participate and to give written informed consent

You may not qualify if:

  • Contra-indications to tDCS use:
  • Presence of a cardiac or neurological condition
  • Metallic implants
  • If contact with scalp is not possible
  • Have had a head injury resulting in a loss of consciousness that has required further investigation
  • History of seizures
  • Epilepsy or a history of epilepsy
  • Past adverse effects with non-invasive stimulation treatments
  • Current diagnosis of another psychiatric disorder (except for depression, as long as secondary diagnosis), psychoactive medication or psychological treatment
  • Left-handedness
  • Pregnancy
  • Skin condition on the stimulation target area
  • Recreational drug use

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (4)

  • HAMILTON M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50-5. doi: 10.1111/j.2044-8341.1959.tb00467.x. No abstract available.

    PMID: 13638508BACKGROUND
  • HAMILTON M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960 Feb;23(1):56-62. doi: 10.1136/jnnp.23.1.56. No abstract available.

    PMID: 14399272BACKGROUND
  • Bikson M, Grossman P, Thomas C, Zannou AL, Jiang J, Adnan T, Mourdoukoutas AP, Kronberg G, Truong D, Boggio P, Brunoni AR, Charvet L, Fregni F, Fritsch B, Gillick B, Hamilton RH, Hampstead BM, Jankord R, Kirton A, Knotkova H, Liebetanz D, Liu A, Loo C, Nitsche MA, Reis J, Richardson JD, Rotenberg A, Turkeltaub PE, Woods AJ. Safety of Transcranial Direct Current Stimulation: Evidence Based Update 2016. Brain Stimul. 2016 Sep-Oct;9(5):641-661. doi: 10.1016/j.brs.2016.06.004. Epub 2016 Jun 15.

    PMID: 27372845BACKGROUND
  • Barlow DH, Farchione TJ, Bullis JR, Gallagher MW, Murray-Latin H, Sauer-Zavala S, Bentley KH, Thompson-Hollands J, Conklin LR, Boswell JF, Ametaj A, Carl JR, Boettcher HT, Cassiello-Robbins C. The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders Compared With Diagnosis-Specific Protocols for Anxiety Disorders: A Randomized Clinical Trial. JAMA Psychiatry. 2017 Sep 1;74(9):875-884. doi: 10.1001/jamapsychiatry.2017.2164.

    PMID: 28768327BACKGROUND

MeSH Terms

Conditions

Anxiety Disorders

Interventions

Transcranial Direct Current Stimulation

Condition Hierarchy (Ancestors)

Mental Disorders

Intervention Hierarchy (Ancestors)

Electric Stimulation TherapyTherapeuticsConvulsive TherapyPsychiatric Somatic TherapiesBehavioral Disciplines and ActivitiesElectroshockPsychological Techniques

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Integrated Researcher

Study Record Dates

First Submitted

June 26, 2020

First Posted

July 1, 2020

Study Start

January 3, 2023

Primary Completion

January 1, 2024

Study Completion

July 1, 2024

Last Updated

May 20, 2022

Record last verified: 2022-05

Data Sharing

IPD Sharing
Will share